Koya Medical is a transformative healthcare company focused on developing breakthrough treatments for venous diseases and lymphedema and providing personalized care. Led by CEO Andy Doraiswamy, the company aims to address substantial unmet needs for patients with progressive, incurable lymphedema. An estimated 20 million Americans live with lymphedema, which can result from cancer, chronic venous disease, infection, and surgery and often requires lifelong management. Koya plans to use the newly raised capital to support strategic expansion and continued growth. The company raised up to $30M in financing in a round led by OrbiMed. Koya is based in Oakland, CA. Koya Medical is a healthcare company developing wearable active compression systems to treat lymphedema and venous disorders. Its lead product, the Dayspring system, is a low-profile, mobility-enabled active compression therapy cleared by the U.S. FDA to treat lymphedema and similar conditions in the upper and lower extremities. Dayspring includes a soft, breathable garment using Koya’s proprietary Flexframe technology, a rechargeable handheld controller, and a mobile app for therapy tracking and custom programming. The company plans to use new funding to accelerate expansion and commercialization of Dayspring and to continue platform development and clinical research to pursue additional indications. Koya positions its technology to enable movement and muscle use to promote healthy fluid flow and improve quality of life compared with traditional compression. The privately held company was founded in 2018 and emphasizes patient-centric design. Koya Medical develops the Dayspring prescription-only active wearable compression system for treating lymphedema and venous insufficiency. Dayspring is FDA-cleared and is described as the first digitally connected system designed to enable patient mobility during use. The company is based in Oakland, Calif., and was founded in 2018. Andy Doraiswamy, PhD, serves as President and CEO. Koya recently closed an $11M Series A financing led by Arboretum Ventures. Jan Garfinkle of Arboretum will join the board while Josh Baltzell will continue as Chairman.

Total raised

$67M

Funding rounds

3

Latest round

Equity

Latest activity

Nov 2023